Trial Profile
Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients with non-malignant diseases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Treosulfan (Primary) ; Busulfan
- Indications Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders
- Focus Therapeutic Use
- Sponsors Medac
- 02 Nov 2023 Status changed from active, no longer recruiting to completed.
- 02 May 2023 This trial has been completed in Poland (End date: 13-Feb 2023).
- 25 Apr 2023 This trial has been completed in Germany (End date: 13-Feb 2023).